Company news
Vector Science And Therapeutics Corp. (TSXV:PAIN) news
Vector Science And Therapeutics Corp. news releases on 6ix. Latest, Sep 25, 2026: Vector Science and Therapeutics Corp. Issues Options
Press releases & updates
Vector Science and Therapeutics Corp. Issues Options
September 25, 2026
Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options
August 24, 2026
Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online
August 24, 2026
Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
August 20, 2026
Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings
August 17, 2026
Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products
July 28, 2026
Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
July 24, 2026
Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels
July 21, 2026
Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
July 17, 2026
Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies
July 15, 2026
Darryl Drake Jr. Named President of Valor as Vector Science and Therapeutics Targets the Performance Medicine Market
July 8, 2026
Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
July 7, 2026
Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform
June 30, 2026
Gary Payton II Named Chief Athletic Ambassador of Valor
June 22, 2026
Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
June 12, 2026
Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor
June 8, 2026
Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy
June 2, 2026
/C O R R E C T I O N -- Vector Sciences & Therapeutics/
May 19, 2026
Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing
May 13, 2026
Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC
May 11, 2026
Vector Science & Therapeutics Expands Board of Directors with Appointment of Dr. Alexander Dobranowski and Scott Kelly
May 6, 2026
Vector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery
May 1, 2026
Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board
April 30, 2026
Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange
April 24, 2026